Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Results from a retrospective case-control study indicate that the pneumococcal vaccine provides significant protection in all HIV-infected patients, not just those with CD4 counts ≥200 cells/mm 3.

Pfizer PFE is a key player in the PCV vaccine space. PFE markets Prevnar 20, which is approved for the prevention of IPD caused by 20 serotypes in individuals aged six weeks and older. PFE also ...

Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Last week, Vaxcyte reported top-line results from the mid-stage study that evaluated its 24-valent PCV VAX-24 against Pfizer’s PFE Prevnar 20. The Pfizer vaccine is approved for preventing ...